IBDEI1VP ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33052,1,4,0)
 ;;=4^K71.2
 ;;^UTILITY(U,$J,358.3,33052,2)
 ;;=^5008796
 ;;^UTILITY(U,$J,358.3,33053,0)
 ;;=K71.3^^182^1995^27
 ;;^UTILITY(U,$J,358.3,33053,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33053,1,3,0)
 ;;=3^Toxic Liver Disease w/ Chronic Persistent Hepatitis
 ;;^UTILITY(U,$J,358.3,33053,1,4,0)
 ;;=4^K71.3
 ;;^UTILITY(U,$J,358.3,33053,2)
 ;;=^5008797
 ;;^UTILITY(U,$J,358.3,33054,0)
 ;;=K71.4^^182^1995^26
 ;;^UTILITY(U,$J,358.3,33054,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33054,1,3,0)
 ;;=3^Toxic Liver Disease w/ Chronic Lobular Hepatitis
 ;;^UTILITY(U,$J,358.3,33054,1,4,0)
 ;;=4^K71.4
 ;;^UTILITY(U,$J,358.3,33054,2)
 ;;=^5008798
 ;;^UTILITY(U,$J,358.3,33055,0)
 ;;=K75.81^^182^1995^19
 ;;^UTILITY(U,$J,358.3,33055,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33055,1,3,0)
 ;;=3^Nonalcoholic Steatohepatitis (NASH)
 ;;^UTILITY(U,$J,358.3,33055,1,4,0)
 ;;=4^K75.81
 ;;^UTILITY(U,$J,358.3,33055,2)
 ;;=^5008828
 ;;^UTILITY(U,$J,358.3,33056,0)
 ;;=K75.89^^182^1995^16
 ;;^UTILITY(U,$J,358.3,33056,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33056,1,3,0)
 ;;=3^Inflammatory Liver Disease,Oth Spec
 ;;^UTILITY(U,$J,358.3,33056,1,4,0)
 ;;=4^K75.89
 ;;^UTILITY(U,$J,358.3,33056,2)
 ;;=^5008829
 ;;^UTILITY(U,$J,358.3,33057,0)
 ;;=K76.4^^182^1995^21
 ;;^UTILITY(U,$J,358.3,33057,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33057,1,3,0)
 ;;=3^Peliosis Hepatis
 ;;^UTILITY(U,$J,358.3,33057,1,4,0)
 ;;=4^K76.4
 ;;^UTILITY(U,$J,358.3,33057,2)
 ;;=^91041
 ;;^UTILITY(U,$J,358.3,33058,0)
 ;;=K71.50^^182^1995^24
 ;;^UTILITY(U,$J,358.3,33058,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33058,1,3,0)
 ;;=3^Toxic Liver Disease w/ Chronic Active Hepatitis w/o Ascites
 ;;^UTILITY(U,$J,358.3,33058,1,4,0)
 ;;=4^K71.50
 ;;^UTILITY(U,$J,358.3,33058,2)
 ;;=^5008799
 ;;^UTILITY(U,$J,358.3,33059,0)
 ;;=K71.51^^182^1995^25
 ;;^UTILITY(U,$J,358.3,33059,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33059,1,3,0)
 ;;=3^Toxic Liver Disease w/ Chronic Active Hepatitis w/o Ascites
 ;;^UTILITY(U,$J,358.3,33059,1,4,0)
 ;;=4^K71.51
 ;;^UTILITY(U,$J,358.3,33059,2)
 ;;=^5008800
 ;;^UTILITY(U,$J,358.3,33060,0)
 ;;=K71.7^^182^1995^28
 ;;^UTILITY(U,$J,358.3,33060,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33060,1,3,0)
 ;;=3^Toxic Liver Disease w/ Fibrosis & Cirrhosis of Liver
 ;;^UTILITY(U,$J,358.3,33060,1,4,0)
 ;;=4^K71.7
 ;;^UTILITY(U,$J,358.3,33060,2)
 ;;=^5008802
 ;;^UTILITY(U,$J,358.3,33061,0)
 ;;=K71.8^^182^1995^32
 ;;^UTILITY(U,$J,358.3,33061,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33061,1,3,0)
 ;;=3^Toxic Liver Disease w/ Oth Disorders of Liver
 ;;^UTILITY(U,$J,358.3,33061,1,4,0)
 ;;=4^K71.8
 ;;^UTILITY(U,$J,358.3,33061,2)
 ;;=^5008803
 ;;^UTILITY(U,$J,358.3,33062,0)
 ;;=K71.9^^182^1995^33
 ;;^UTILITY(U,$J,358.3,33062,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33062,1,3,0)
 ;;=3^Toxic Liver Disease,Unspec
 ;;^UTILITY(U,$J,358.3,33062,1,4,0)
 ;;=4^K71.9
 ;;^UTILITY(U,$J,358.3,33062,2)
 ;;=^5008804
 ;;^UTILITY(U,$J,358.3,33063,0)
 ;;=K75.2^^182^1995^20
 ;;^UTILITY(U,$J,358.3,33063,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33063,1,3,0)
 ;;=3^Nonspecific Reactive Hepatitis
 ;;^UTILITY(U,$J,358.3,33063,1,4,0)
 ;;=4^K75.2
 ;;^UTILITY(U,$J,358.3,33063,2)
 ;;=^5008826
 ;;^UTILITY(U,$J,358.3,33064,0)
 ;;=K75.3^^182^1995^13
 ;;^UTILITY(U,$J,358.3,33064,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33064,1,3,0)
 ;;=3^Granulomatous Hepatitis NEC
 ;;^UTILITY(U,$J,358.3,33064,1,4,0)
 ;;=4^K75.3
 ;;^UTILITY(U,$J,358.3,33064,2)
 ;;=^5008827
 ;;^UTILITY(U,$J,358.3,33065,0)
 ;;=F02.80^^182^1996^9
 ;;^UTILITY(U,$J,358.3,33065,1,0)
 ;;=^358.31IA^4^2
 ;;
 ;;$END ROU IBDEI1VP
